Democratic Republic of Congo

Ebola Treatments Trial Begins in DR Congo

Is this a landmark step forward in global health or a drop in the ocean of an overwhelming crisis?

Published 3 days ago

Ebola Treatments Trial Begins in DR Congo

story

Above: A worker at the Ebola Treatment Center of the Center Médical Évangélique (CME) in eastern DRC on June 23. Image credit: Benediction Murhabazi/AFP/Getty Images

The Spin

Narrative A

The PARTNERS trial is a landmark moment in global health — for the first time, patients with Bundibugyo virus disease can access promising investigational treatments like MBP134 and remdesivir during an active outbreak. Running research alongside the outbreak response, not after it, means evidence can reshape patient care in months rather than years. This is the kind of coordinated, science-driven action that saves lives.

RFI

Tedros Adhanom Ghebreyesus on WHO Science

Narrative B

Launching a clinical trial means little when the outbreak is spreading faster than any Ebola event on record, conflict blocks aid workers and 15 million people face a simultaneous humanitarian crisis. No approved vaccine exists for Bundibugyo, funding pledges keep falling short and cholera and measles are compounding pressure on an already overwhelmed health system. A trial is a start, but the response is nowhere near the scale this crisis demands.

The Eastleigh Voice News Guardian The Washington Examiner Oxfam International

Establishment-critical narrative

The PARTNERS rollout in the DRC may be framed as medical progress, but many Africans still remember being treated as the world's medical testing ground. From colonial-era abuses to Ebola-era drug trials, trust has repeatedly been broken. Any rollout of investigational treatments during outbreaks must guarantee informed consent, local oversight and access to successful therapies.